The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers
Open accessAbstract
Over the past few decades, trans-resveratrol has received widespread attention as a preventive agent for numerous diseases. Several studies have demonstrated that it has significant biological and pharmacological properties. Trans-resveratrol has been reported to possess anti-oxidant, anti-inflammatory, anticarcinogenic, antidiabetic, anti‑aging, cardioprotective and neuroprotective properties, which can be relevant in chronic diseases and longevity in humans. The aim of the present study was to investigate the rate and extend of absorption, and also the safety of resveratrol following a single 500 mg oral dose. This was an open label, single dose, one period, bioavailability study in 15 healthy volunteers under fasting conditions. Blood samples were collected at predefined time points up to 24 h after resveratrol administration, and plasma concentrations of resveratrol and its conjugated (glucuronated and sulphated) metabolites were determined using a validated high performance liquid chromatography/tandem mass spectrometry method. Pharmacokinetic parameters, including Cmax, AUC0‑t, AUC0‑inf, Tmax, T1/2 and MRT, were determined from plasma concentration‑time profiles and found to be in good agreement with previously reported data. Cmax and AUC0‑inf were lower for resveratrol when compared with the values for its glucuronated and sulphated metabolites. Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0‑inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively. No adverse reactions associated with resveratrol were reported during the study. The plasma concentrations of resveratrol (free and conjugated) were in agreement with those mentioned in the literature, and were adequate to promote the pharmacological activities of resveratrol. In conclusion, resveratrol 500 mg tablets were well-tolerated by all participants of the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051
Inhibition of cancer growth by resveratrol is related to its low bioavailability
Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., & Estrela, J. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00911-5 · Cited by 388
Cited by
Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403
Health benefits of resveratrol administration
Galiniak, S., Aebisher, D., & Bartusik-Aebisher, D. (2019) · Acta Biochimica Polonica · doi:10.18388/abp.2018_2749 · Cited by 333
Resveratrol and Its Effects on the Vascular System
Breuss, J. M., Atanasov, A. G., & Uhrin, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071523 · Cited by 328
Resveratrol and Its Human Metabolites—Effects on Metabolic Health and Obesity
Springer, M., & Moco, S. (2019) · Nutrients · doi:10.3390/nu11010143 · Cited by 291
Huang, C.-C., Liu, C.-C., Tsao, J.-P., Hsu, C.-L., & Cheng, I.-S. (2020) · Nutrients · doi:10.3390/nu12123721 · Cited by 16
Metadata
- Authors
- SERGIDES, C., CHIRILĂ, M., SILVESTRO, L., PITTA, D., & PITTAS, A.
- Venue
- Experimental and Therapeutic Medicine
- Publisher
- Spandidos Publications
- Published
- 2015-11-25
- Volume
- 11
- Issue
- 1
- Pages
- 164-170
- ISSN
- 1792-0981 (ISSN-L)
- 1792-1015
- OpenAlex
- W2172640301
- Cited by
- 209
- References
- 2
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. https://app.cochat.ai/papers/10.3892/etm.2015.2895
- The paper
- SERGIDES, C., CHIRILĂ, M., SILVESTRO, L., PITTA, D., & PITTAS, A. (2016). Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Experimental and Therapeutic Medicine. https://doi.org/10.3892/etm.2015.2895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.